CA2895131A1 - Medicament for atrophy treatment or increasing cell growth - Google Patents

Medicament for atrophy treatment or increasing cell growth Download PDF

Info

Publication number
CA2895131A1
CA2895131A1 CA2895131A CA2895131A CA2895131A1 CA 2895131 A1 CA2895131 A1 CA 2895131A1 CA 2895131 A CA2895131 A CA 2895131A CA 2895131 A CA2895131 A CA 2895131A CA 2895131 A1 CA2895131 A1 CA 2895131A1
Authority
CA
Canada
Prior art keywords
cells
serf2
cell
muscle
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2895131A
Other languages
English (en)
French (fr)
Inventor
Rudolf Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIMU TRADE CONSULTING & Co LEASING KG GmbH
Original Assignee
SIMU TRADE CONSULTING & Co LEASING KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIMU TRADE CONSULTING & Co LEASING KG GmbH filed Critical SIMU TRADE CONSULTING & Co LEASING KG GmbH
Publication of CA2895131A1 publication Critical patent/CA2895131A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2895131A 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth Abandoned CA2895131A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197192.3 2012-12-14
EP12197192.3A EP2742935A1 (en) 2012-12-14 2012-12-14 SERF2 for the treatment of atrophy and for increasing cell growth
PCT/EP2013/076547 WO2014090991A1 (en) 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth

Publications (1)

Publication Number Publication Date
CA2895131A1 true CA2895131A1 (en) 2014-06-19

Family

ID=47355920

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2895131A Abandoned CA2895131A1 (en) 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth

Country Status (7)

Country Link
US (2) US9637529B2 (cg-RX-API-DMAC7.html)
EP (2) EP2742935A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016508123A (cg-RX-API-DMAC7.html)
CN (1) CN105163726A (cg-RX-API-DMAC7.html)
AU (1) AU2013357283A1 (cg-RX-API-DMAC7.html)
CA (1) CA2895131A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014090991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913047A2 (pt) 2008-05-23 2013-03-05 Siwa Corp anticorpo monoclonal humanizado, seu uso, bem como aparelho e mÉtodo in vitro para promover processos regenerativos em uma cultura de tecido ou cultura de cÉlula
MA40459A (fr) 2014-09-19 2016-03-24 Siwa Corp Anticorps anti-age pour le traitement de l'inflammation et de troubles auto-immuns
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
AU2017250301A1 (en) 2016-04-15 2018-11-15 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3475306A1 (en) 2016-06-23 2019-05-01 Siwa Corporation Vaccines for use in treating various diseases and disorders
EP3549589A4 (en) * 2016-11-30 2020-07-15 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
BR112019021471A2 (pt) 2017-04-13 2020-05-12 Siwa Corporation Anticorpo monoclonal humanizado de produto final da glicação avançada
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN113337460A (zh) * 2021-06-10 2021-09-03 呼和浩特职业学院 一种绵羊骨骼肌卫星细胞的高效分离和纯化方法
CN118108828B (zh) * 2022-11-29 2025-10-28 上海众启生物科技有限公司 含有serf2的蛋白抗原组合及其应用
CN117538545B (zh) * 2024-01-09 2024-07-05 上海众启生物科技有限公司 一种用于阿尔茨海默症检测的蛋白抗原组合及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
CA2399776A1 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
CN105163726A (zh) 2015-12-16
JP2016508123A (ja) 2016-03-17
US20150307568A1 (en) 2015-10-29
US9637529B2 (en) 2017-05-02
US20170253641A1 (en) 2017-09-07
EP2931264A1 (en) 2015-10-21
EP2742935A1 (en) 2014-06-18
AU2013357283A1 (en) 2015-07-09
WO2014090991A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
US9637529B2 (en) Medicament for atrophy treatment or increasing cell growth
Wang et al. Slit3 secreted from M2-like macrophages increases sympathetic activity and thermogenesis in adipose tissue
Fernandez et al. Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype
Wu et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis
Schuger et al. Retinoic acid stimulates mouse lung development by a mechanism involving epithelial-mesenchymal interaction and regulation of epidermal growth factor receptors
Miyashita et al. The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in ischemic brain and its therapeutic potential
KR102379045B1 (ko) 내피 집락 형성 세포­유사 세포를 생성하는 방법
KR20190102015A (ko) 생체 조직 손상의 수복제 및 그 수복제의 제조 방법
Hashimoto et al. Long-term activation of c-Fos and c-Jun in optic nerve head astrocytes in experimental ocular hypertension in monkeys and after exposure to elevated pressure in vitro
Bae et al. Intracellular Calcium Determines the Adipogenic Differentiation Potential of Human Umbilical Cord Blood‐Derived Mesenchymal Stem Cells via the Wnt5a/β‐Catenin Signaling Pathway
Xu et al. IL-18 promotes erythrophagocytosis and erythrocyte degradation by M1 macrophages in a calcific microenvironment
Cancedda et al. Ex-FABP: a fatty acid binding lipocalin developmentally regulated in chicken endochondral bone formation and myogenesis
Usui-Kusumoto et al. Suppression of neovascularization in corneal stroma in a TRPA1-null mouse
Niu et al. Klotho enhances bone regenerative function of hPDLSCs via modulating immunoregulatory function and cell autophagy
Wang et al. Characterization of proliferating cells from newborn mouse cochleae
US20170216416A1 (en) Pigment Epithelium-Derived Factor (PEDF) and Peptide Derivatives Thereof for Use in Osteoblast Differentiation and Bone Growth
JP2020509768A (ja) エネルギー代謝を調節するポリペプチド及びその使用
KR20160034176A (ko) Oct4 및 Sox2를 과발현하는 중간엽줄기세포 및 그 용도
Ai et al. Retinal blood vessel‐origin yes‐associated protein (YAP) governs astrocytic maturation via leukaemia inhibitory factor (LIF)
Chung et al. TGF-β-stimulated aberrant expression of class III β-tubulin via the ERK signaling pathway in cultured retinal pigment epithelial cells
Kaiser et al. Brain stem slice conditioned medium contains endogenous BDNF and GDNF that affect neural crest boundary cap cells in co-culture
WO2004073731A1 (en) 14-3-3 protein for prevention and treatment of fibroproliferative disorders
Peng et al. Inhibition of p38 MAPK facilitates ex vivo expansion of skin epithelial progenitor cells
JP2021521113A (ja) 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用
TWI902659B (zh) Ｐｅｄｆ衍生之短肽在肌腱癒合中的應用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181213